2024-05-13T16:45:26+00:00 2023-06-30 350921680 CROWE LLP 9600 Brownsboro Road Suite 400 Louisville KY 402413902 990 2022-07-01 260303542 Hoosier Cancer Research Network Inc HOOS 3179212050 7676 Interactive Way 120 Indianapolis IN 462782736 Brian Stemme CEO 3179212050 2024-05-13 true Brian Stemme 999009999 Kim Scifres P01316095 5023263996 2022 2023-04-26 12:10:37Z Brian Stemme 7676 Interactive Way 120 Indianapolis IN 462782736 16600746 false X www.hoosiercancer.org X 2007 IN To reduce the burden of cancer by advancing cancer research, education, and patient advocacy. 9 9 65 9 0 0 722381 695094 9317631 13210958 270692 195606 0 10310704 14101658 0 0 4724775 5050230 0 0 6664355 6980422 11389130 12030652 -1078426 2071006 10358529 13703057 2648037 3864540 7710492 9838517 To form unparalleled relationships between academic, community, pharmaceutical, and biotech collaborators with the goal of advancing cancer research, education, and patient advocacy. false false 10048021 12835958 INVESTIGATOR-INITIATED STUDIES - THESE ARE STUDIES CREATED BY NON-INDUSTRY PHYSICIANS, MOST COMMONLY FOR US FROM ACADEMIC INSTITUTIONS BUT POSSIBLY ALSO FROM COMMUNITY SITES, AND THOSE PHYSICIANS SERVE AS SPONSOR-INVESTIGATORS. WHEN WE CONDUCT/MANAGE THESE STUDIES, WE PRESERVE RIGHTS FOR US AND OUR MEMBER INSTITUTIONS TO PUBLISH AND ACCESS DATA FOR THE PUBLIC BENEFIT CONSISTENT WITH OUR TAX EXEMPT PURPOSE. THESE STUDIES MAY BE FUNDED BY INDUSTRY, BUT INDUSTRY IS NOT THE SPONSOR. THE SPONSOR INVESTIGATOR OWNS THE PROTOCOL AND DATA IN AN IIT AND INDUSTRY GETS TO USE THE DATA. 420948 375000 GOVERNMENT PROGRAMS - THE ORGANIZATION TEAMS UP WITH LOCAL UNIVERSITIES, HOSPITALS, AND OTHER COMMUNITY HEALTH ORGANIZATIONS IN ORDER TO PERFORM FEDERAL CONTRACT RESEARCH IN THE CANCER COMMUNITY. THROUGH SUBAWARDS WITH VARIOUS UNIVERSITIES, HOOSIER CANCER RESEARCH NETWORK CONDUCTS PATIENT RESEARCH WITH VARIOUS FEDERAL CANCER PROGRAMS. INDUSTRY-SPONSORED STUDIES - ON RARE OCCASIONS, WE GET INVOLVED IN INDUSTRY-SPONSORED STUDIES, MEANING A STUDY INITIATED AND CONDUCTED BY A PHARMACEUTICAL COMPANY. WHEN WE WORK ON THOSE STUDIES, WE PRESERVE RIGHTS FOR US AND OUR SITES TO PUBLISH AND ACCESS DATA FOR THE PUBLIC BENEFIT CONSISTENT WITH OUR TAX-EXEMPT PURPOSE. WE DO NOT WORK ON INDUSTRY-SPONSORED STUDIES IN WHICH WE CANNOT PRESERVE PUBLICATION AND DATA ACCESS RIGHTS FOR US AND OUR MEMBER SITES (BECAUSE TO DO SO WOULD BE INCONSISTENT WITH OUR TAX EXEMPT PURPOSE). PHARMA FUNDS THESE STUDIES AND ALSO ACTS AS THE SPONSOR. PHARMA OWNS THE PROTOCOL AND DATA IN THESE STUDIES, AND SITES (AND WE) GET TO USE THE DATA FOR PUBLICATION PURPOSES. 10468969 true false false false false false false false false true false false true true true true false false false false false false false false false false false false true false false false false false false false false false false false false false true false false false true 22 0 true 65 true false false false false false false false false false false false false X 9 9 false false false false false true false true true false false true true true true true true true false false IN X Mark Ingold 3179212050 7676 Interactive Way Ste 120 Indianapolis IN 462782736 Annette Moore MD Secretary 0.5 X X 0 0 0 Chris Fausel Chair 1.0 X X 0 0 0 Chris Wayne Treasurer 0.5 X X 0 0 0 Alesha Arnold Board Member (Until Feb. 2023) 0.2 40.0 X 0 92426 0 Chris LeMasters Board Member 0.5 X 0 0 0 Jennifer King MD Board Member 0.5 40.0 X 0 67951 0 Patrick Loehrer MD Board Member 0.5 40.0 X 0 302507 0 Richard Zellars MD board member (Until May 2023) 0.2 X 0 0 0 Rita Assi MD Board Member 0.5 X 0 0 0 Ted Stansberry Board Member (Until May 2023) 0.2 X 0 0 0 Tim Lautenschlaeger MD Board Member 0.5 40.0 X 0 40780 0 Tim Ratliff PhD Board Member 0.5 X 0 0 0 Brian Stemme CEO (Hired Aug 22) 40.0 X 90542 0 14462 Cindy Burkhardt Executive Director (until 9/30/22) 40.0 X 172334 0 5275 Jeff Smith COO 40.0 X 113263 0 15809 JoLynn Bahr CFO 40.0 X 156079 0 28236 Anita Camic Contracts and Quality Assurance Officer 40.0 X 103793 0 13615 Christy Yoder Safety and Regulatory Officer 40.0 X 107469 0 32184 Karen Dutcher General Counsel 40.0 X 135905 0 16848 LeaEtta Hyer Research Development Officer 40.0 X 120752 0 33570 Lisa Wood Research Development Director 40.0 X 102947 0 15221 1103084 503664 175220 8 false true false 0 692135 2959 695094 External Support-Research 541715 12835958 12835958 0 0 Other Contract Support 541715 375000 375000 0 0 0 0 0 0 13210958 194662 194662 0 0 2500032 2499088 944 0 944 944 0 0 0 0 0 14101658 13210958 0 195606 596000 513353 82647 3417363 2943481 473882 704251 234497 469754 332616 144145 188471 1250 1250 36771 36771 1008210 1008210 0 0 106895 181 106714 1414138 1196825 217313 211892 164965 46927 8077 110 7967 86873 86873 61828 46742 15086 70803 53528 17275 Institutional Research 2597580 2597580 Other Research Services 992691 992691 Lab Supplies 447621 447621 Bad Debt Expense -87500 -87500 23293 146 23147 0 12030652 10468969 1561683 0 200 200 2623279 4559016 4742513 4609794 0 0 0 0 644156 483132 210601 161024 2756936 2928505 0 0 25000 0 0 1444518 10358529 13703057 2273025 2208449 375012 187500 0 0 0 1468591 2648037 3864540 X 7536655 9664680 173837 173837 7710492 9838517 10358529 13703057 2071006 57019 0 X false true X true false X X X 1 INDIANA UNIVERSITY 356001673 2 true 426885 0 1 426885 0 true false false false false false false false false false false false false false false true false 644156 483132 161024 161024 Right of Use Assets 1444518 1444518 Lease Liability 1468591 1468591 X 14158677 57019 0 57019 14101658 0 0 14101658 12030652 0 0 12030652 0 0 12030652 Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote The Organization is exempt from federal income taxes under Section 501(c)(3) of the U.S. Internal Revenue Code and is not considered to be a private foundation. Current accounting standards require the Organization to disclose the amount of potential benefit or obligation to be realized as a result of an examination performed by a taxing authority. For the years ended June 30, 2023 and 2022, management has determined that the Organization does not have any tax positions that result in any uncertainties regarding the possible impact on the Organization's financial statements. The Organization does not expect the total amount of unrecognized tax benefits to significantly change in the next 12 months. The Organization recognizes interest and/or penalties related to income tax matters in income tax expense. The Organization did not have any amounts accrued for interest and penalties at June 30, 2023 and 2022. X X X false false false false false false false false false Patrick Loehrer MD Board Member 0 302507 0 0 0 0 0 0 0 0 0 302507 0 0 JoLynn Bahr CFO 134451 0 21628 0 0 0 4841 0 23395 0 184315 0 0 0 Cindy Burkhardt Executive Director (until 9/30/22) 147620 0 24714 0 0 0 5173 0 102 0 177609 0 0 0 LeaEtta Hyer Research Development Officer 103762 0 16990 0 0 0 3840 0 29730 0 154322 0 0 0 Karen Dutcher General Counsel 126796 0 9109 0 0 0 4602 0 12246 0 152753 0 0 0 Form 990, Part VI, Line 1a Delegate broad authority to a committee The Executive Committee shall be composed entirely of directors. During intervals between meetings of the Board of Directors, the Executive Committee shall have and exercise all of the authority of the Board of Directors in the management of the Corporation, except where prohibited by law. In addition, the Executive Committee, to the extent specified by the Board of Directors, may exercise any other authority of the Board of Directors at such other times, except where prohibited by law. Form 990, Part VI, Line 7a Members or stockholders electing members of governing body The Director of the Indiana University Melvin and Bren Simon Cancer Center has authority to appoint a majority of the Board of Directors. Form 990, Part VI, Line 11b Review of form 990 by governing body The form 990 is reviewed in detail by management. Then, a copy of the form 990 is provided to the Chairman for review before it is filed with the Internal Revenue Service. A copy of the 990 is also made available to the Board members at a Board meeting Prior to Filing. Form 990, Part VI, Line 12c Conflict of interest policy A written conflict of interest policy is signed by the board of directors and the CEO annually. The CEO reviews them and discloses any reported conflicts of interest to the board chair. The board chair ensures that any member who has a conflict of interest abstains from voting on issues related to the conflict. Form 990, Part VI, Line 15a Process to establish compensation of top management official The Officers of the Finance Committee review and approve the compensation of the CEO. The board uses performance review information to determine compensation, in conjunction with comparability data including forms 990 of other organizations. This process was last undergone in June 2021. Form 990, Part VI, Line 19 Required documents available to the public Financial statements, governing documents, and conflict of interest policies are not required disclosures pursuant to Internal Revenue Code (IRC) Section 6104. These documents are not available to the public at this time. Form 990, Part VII, Section A, Line 1a Reportable Compensation from related organizations Compensation reported on Part VII and Schedule J for board members who are employees of Indiana University is the compensation annually reported and disclosed by the university as required under state statute. In addition, these individuals participate in retirement and benefit plan provided by the university. Indiana University 400 E 7th St Rm 501 Bloomington IN 47405 356001673 Education IN 501(c)(3) 2 NA false false false false false false false false false false false false false false false false true false false false